References
- McDonald W. I., Compston A., Edan G., Goodkin D., Hartung H. P., Lublin F. D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121–7
- Calin A. Is there an association between ankylosing spondylitis and multiple sclerosis?. Ann Rheum Dis 1989; 48: 971–2
- Optic Neuritis Study Group. The 5‐year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. 1997. Neurology 2001; 57((12 Suppl 5))S36–45
- Sicotte N. L., Voskuhl R. R. Onset of multiple sclerosis associated with anti‐TNF therapy. Neurology 2001; 57: 1885–8
- Gomez‐Gallego M., Meca‐Lallana J., Fernandez‐Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol 2008; 59: 91–3
- Enayati P. J., Papadakis K. A. Association of anti‐tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 2005; 39: 303–6
- Bellesi M., Logullo F., Di Bella P., Provinciali L. CNS demyelination during anti‐tumor necrosis factor alpha therapy. J Neurol 2006; 253: 668–9
- Bensouda‐Grimaldi L., Mulleman D., Valat J. P., Autret‐Leca E. Adalimumab‐associated multiple sclerosis. J Rheumatol 2007; 34: 239–40
- Magnano M. D., Robinson W. H., Genovese M. C. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 2004; 22((5 Suppl 35))S134–40
- The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo‐controlled multicenter study. Neurology 1999; 53: 457–65